Skip to content

Development of Eye-tracking Based Markers for Autism in Young Children

Evaluation of Five Different Eye-tracking Paradigms to Determine Autism in Young Children

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03286621
Enrollment
70
Registered
2017-09-18
Start date
2017-09-09
Completion date
2018-02-28
Last updated
2018-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder

Keywords

eye tracking, visual preference

Brief summary

The main aim of the present study is to examine eye-tracking based markers for social processing deficits in children with autism spectrum disorder (ASD). To this end a battery of five eye-tracking paradigms will be administered to young children with ASD and typically developing children. To additionally evaluate the specificity of the eye-tracking markers a group of children with disorders of delayed development other than ASD will be included.

Detailed description

During an initial screening session all participants will undergo the Autism Diagnostic Observation Schedule (ADOS). ASD-related symptomatology and levels of impairments will be further characterized using the Social Responsibilities Scale 2 (SRS 2), Caregiver Strain Questionnaire (CSQ), Aberrant Behavior Checklist (ABC), Social Communication Questionnaire (SCQ), and Repetitive Behaviour Scale Revised (RBS-R). Subsequently all participants will be administered the following eye-tracking paradigms: (1) dynamic social and non-social visual preference paradigm during which dynamic geometric images (DGI) and dynamic social images (DSI) will be presented, (2) non-biological versus biological motion paradigm, (3) social attention and sharing of enjoyment paradigm, (4) preference for real versus schematic emotional face stimuli paradigm during which photographs of human faces and emoticons will be presented, (5) shared social attention and gaze direction paradigm.

Interventions

OTHERAdministration of five eye-tracking paradigms

All subjects will undergo the battery of five eye-tracking paradigms to determine potential markers for autism.

Sponsors

University of Electronic Science and Technology of China
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
12 Months to 10 Years
Healthy volunteers
Yes

Exclusion criteria

for all participants: * visual, auditory or motor impairments * use of medication Inclusion criteria for all participants: * written informed consent from parents / caregiver * age: 1-10 years Additional inclusion criterion for the ASD group: \- diagnosis of Autism Spectrum Disorder according to DSM-5 Additional inclusion criteria for typically developing children in the control group: * no symptoms of developmental disorders * no current or history of psychological disorder Additional inclusion criterion for the unspecific disorder of delayed development children in the additional control group: \- disorder of delayed development other than ASD

Design outcomes

Primary

MeasureTime frameDescription
Global eye-gaze characteristicsSingle assessment, total duration 20 minutesGlobal eye-gaze patterns between the three groups will be compared to determine ASD specific alterations
Feature-specific eye-gaze characteristicsSingle assessment, total duration 20 minutesLocalized feature-specific eye-gaze patterns will be compared between the three groups to determine ASD specific alterations

Secondary

MeasureTime frameDescription
Global eye-gaze characteristics and associations with symptom severitySingle assessment, total duration 20 minutesAssociations between global eye-gaze characteristics and severity of ASD symptoms
Feature-specific eye-gaze characteristics and associations with symptom severitySingle assessment, total duration 20 minutesAssociations between localized feature-specific eye-gaze patterns and severity of ASD symptoms

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026